Results from the Andrew P. Lieberman Lab are Published

By Lidija Fremeau | November 20 2019

Mark Schultz, PhD, and Andrew Lieberman MD, PhD, have published Mark SchultzSynthetic high-density lipoprotein nanoparticles for the treatment of Niemann–Pick diseases” in BMC Medicine. Their research worked specifically to develop new therapeutics for Niemann-Pick disease type C by harnessing the body’s endogenous cholesterol scavenging particle, high-density lipoprotein (HDL). Niemann–Pick disease type C is a fatal and progressive neurodegenerative disorder characterized by the accumulation of unesterified cholesterol in late endosomes and lysosomes.  Their data establishes that sHDL nanoparticles are a potential new therapeutic avenue for Niemann-Pick diseases.